Cambridge, England - Upfront Diagnostics, a pioneering biotechnology company based in Cambridge, United Kingdom, is thrilled to announce the successful completion of its latest funding round, raising an impressive amount of $2,037,200. The funding was led by APEX Ventures, a renowned venture capital firm known for its strategic investments in transformative technologies.

Founded in November 2017 by visionary entrepreneur Gonzalo Ladreda, Upfront Diagnostics is a dynamic organization comprised of exceptionally talented Cambridge students and young entrepreneurs. Their team is dedicated to discovering biomarkers that can revolutionize medical diagnosis and lead to significant advancements in patient care.

Gonzalo Ladreda, the founder of Upfront Diagnostics, expressed his gratitude for the unwavering support received from APEX Ventures and the entire investor community. "We are thrilled to have APEX Ventures as our lead investor and partners who share our passion for transforming healthcare through innovative diagnostics. This funding marks a significant milestone in our journey. It will enable us to accelerate the development of LVOne, bringing us one step closer to making a profound impact on stroke diagnosis and patient care."